SLC2A1 and glioma: At late‐stage growth (4 weeks), Glut1 and CD31 immunostaining revealed a profound “normalization” of blood vessel parameters in anti‐CSF1 antibody‐treated glioma‐bearing mice compared to isotype‐matched control antibody treatment (Fig 5A and B).